Table 1

Summary treatment effects from the network meta-analysis for failure to achieve an improvement in global IBS symptoms at first point of follow-up post-treatment

CMN/AN/A0.63 (0.29; 1.37)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A0.45 (0.22; 0.92)N/AN/A
0.95 (0.32; 2.82)Group CBTN/AN/AN/AN/A0.83 (0.31; 2.25)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A0.40 (0.18; 0.90)N/A
0.79 (0.34; 1.86)0.83 (0.33; 2.14)Phone CBTN/AN/AN/AN/AN/AN/AN/A0.80 (0.47; 1.35)N/AN/AN/AN/AN/AN/AN/A0.46 (0.28; 0.77)N/AN/A
0.73 (0.35; 1.53)0.76 (0.29; 2.01)0.92 (0.46; 1.84)SMN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A0.57 (0.34; 0.94)N/AN/A
0.68 (0.30; 1.53)0.71 (0.28; 1.79)0.86 (0.46; 1.61)0.94 (0.49; 1.78)DPTN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A0.61 (0.41; 0.91)N/AN/A
0.65 (0.30; 1.42)0.68 (0.29; 1.57)0.82 (0.46; 1.45)0.89 (0.48; 1.65)0.95 (0.56; 1.63)S-A/MC CBT0.91 (0.58; 1.42)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A0.70 (0.41; 1.19)0.33 (0.15; 0.71)0.73 (0.48; 1.09)N/A
0.63 (0.30; 1.35)0.66 (0.30; 1.49)0.80 (0.46; 1.37)0.87 (0.49; 1.55)0.93 (0.57; 1.52)0.98 (0.70; 1.36)F-t-F CBTN/AN/AN/AN/AN/AN/AN/AN/A0.90 (0.53; 1.51)N/A0.73 (0.53; 1.00)0.89 (0.59; 1.33)0.40 (0.27; 0.58)N/A
0.64 (0.25; 1.60)0.67 (0.26; 1.73)0.80 (0.38; 1.69)0.88 (0.40; 1.91)0.94 (0.46; 1.92)0.98 (0.53; 1.82)1.01 (0.56; 1.81)ACTN/AN/AN/AN/AN/AN/AN/AN/A0.72 (0.40; 1.32)N/AN/A0.62 (0.36; 1.05)N/A
0.59 (0.27; 1.30)0.62 (0.27; 1.44)0.75 (0.42; 1.34)0.81 (0.44; 1.51)0.87 (0.51; 1.50)0.91 (0.62; 1.36)0.94 (0.67; 1.32)0.93 (0.50; 1.72)HTN/AN/AN/AN/A0.84 (0.56; 1.24)N/AN/AN/A0.71 (0.51; 1.00)N/A0.76 (0.48; 1.20)N/A
0.59 (0.28; 1.28)0.62 (0.27; 1.46)0.75 (0.43; 1.31)0.82 (0.45; 1.47)0.87 (0.53; 1.45)0.92 (0.60; 1.40)0.94 (0.65; 1.36)0.93 (0.50; 1.74)1.00 (0.66; 1.53)F-t-F MPTN/A0.96 (0.57; 1.63)N/AN/AN/AN/AN/AN/A0.72 (0.50; 1.06)0.63 (0.41; 0.97)N/A
0.56 (0.25; 1.23)0.58 (0.25; 1.39)0.70 (0.43; 1.15)0.77 (0.41; 1.43)0.82 (0.47; 1.42)0.86 (0.54; 1.36)0.88 (0.58; 1.34)0.87 (0.46; 1.67)0.94 (0.59; 1.50)0.94 (0.60; 1.47)Internet CBTN/AN/AN/AN/AN/AN/AN/A0.58 (0.35; 0.96)0.89 (0.55; 1.46)N/A
0.55 (0.24; 1.28)0.58 (0.23; 1.47)0.69 (0.35; 1.35)0.76 (0.38; 1.50)0.81 (0.43; 1.50)0.85 (0.48; 1.51)0.87 (0.51; 1.48)0.86 (0.41; 1.81)0.93 (0.52; 1.65)0.93 (0.57; 1.50)0.99 (0.55; 1.78)Phone MPTN/AN/AN/AN/AN/AN/A0.78 (0.47; 1.29)N/AN/A
0.53 (0.21; 1.35)0.55 (0.20; 1.56)0.66 (0.30; 1.46)0.72 (0.32; 1.61)0.77 (0.37; 1.62)0.81 (0.39; 1.67)0.83 (0.42; 1.65)0.82 (0.35; 1.96)0.89 (0.43; 1.83)0.88 (0.44; 1.78)0.94 (0.46; 1.96)0.96 (0.44; 2.09)Group MPTN/AN/AN/AN/AN/A0.79 (0.42; 1.47)N/AN/A
0.51 (0.23; 1.13)0.53 (0.22; 1.27)0.64 (0.35; 1.17)0.70 (0.37; 1.32)0.75 (0.43; 1.31)0.79 (0.50; 1.23)0.80 (0.54; 1.19)0.80 (0.42; 1.53)0.86 (0.61; 1.21)0.86 (0.54; 1.36)0.91 (0.55; 1.51)0.93 (0.51; 1.68)0.97 (0.46; 2.02)Group HTN/AN/AN/A0.89 (0.54; 1.44)0.71 (0.39; 1.30)N/AN/A
0.50 (0.21; 1.18)0.52 (0.21; 1.29)0.63 (0.32; 1.23)0.69 (0.34; 1.39)0.73 (0.39; 1.39)0.77 (0.46; 1.29)0.79 (0.49; 1.28)0.78 (0.39; 1.55)0.84 (0.51; 1.40)0.84 (0.49; 1.43)0.90 (0.51; 1.58)0.91 (0.47; 1.77)0.95 (0.43; 2.12)0.98 (0.57; 1.70)MMN/AN/A0.57 (0.27; 1.19)N/A0.97 (0.58; 1.64)N/A
0.49 (0.23; 1.05)0.51 (0.22; 1.19)0.61 (0.35; 1.07)0.67 (0.37; 1.20)0.72 (0.43; 1.19)0.75 (0.50; 1.14)0.77 (0.55; 1.08)0.77 (0.41; 1.43)0.82 (0.54; 1.25)0.82 (0.55; 1.23)0.88 (0.56; 1.37)0.89 (0.51; 1.54)0.93 (0.46; 1.86)0.96 (0.61; 1.51)0.98 (0.57; 1.66)RTN/AN/A1.00 (0.70; 1.42)0.70 (0.41; 1.19)0.66 (0.40; 1.09)
0.46 (0.15; 1.39)0.48 (0.16; 1.49)0.58 (0.22; 1.51)0.63 (0.24; 1.70)0.68 (0.27; 1.73)0.71 (0.30; 1.68)0.73 (0.31; 1.69)0.72 (0.40; 1.32)0.78 (0.33; 1.84)0.78 (0.33; 1.85)0.83 (0.34; 2.01)0.84 (0.32; 2.18)0.88 (0.31; 2.52)0.91 (0.37; 2.21)0.92 (0.37; 2.30)0.95 (0.40; 2.25)Internet SMN/AN/AN/AN/A
0.43 (0.20; 0.94)0.46 (0.20; 1.04)0.55 (0.31; 0.96)0.60 (0.33; 1.08)0.64 (0.38; 1.07)0.67 (0.48; 0.94)0.69 (0.53; 0.89)0.68 (0.37; 1.23)0.73 (0.55; 0.97)0.73 (0.49; 1.08)0.78 (0.50; 1.21)0.79 (0.45; 1.37)0.83 (0.41; 1.67)0.85 (0.60; 1.21)0.87 (0.55; 1.38)0.89 (0.61; 1.30)0.94 (0.40; 2.19)E/SN/A0.83 (0.45; 1.53)N/A
0.41 (0.21; 0.83)0.43 (0.19; 0.99)0.52 (0.32; 0.84)0.57 (0.34; 0.94)0.61 (0.41; 0.91)0.64 (0.45; 0.91)0.65 (0.49; 0.87)0.65 (0.36; 1.18)0.70 (0.48; 1.00)0.69 (0.51; 0.95)0.74 (0.51; 1.08)0.75 (0.47; 1.20)0.79 (0.42; 1.47)0.81 (0.55; 1.20)0.83 (0.50; 1.36)0.85 (0.63; 1.15)0.89 (0.38; 2.09)0.95 (0.69; 1.32)RCN/AN/A
0.39 (0.19; 0.84)0.41 (0.19; 0.91)0.50 (0.29; 0.84)0.54 (0.31; 0.96)0.58 (0.36; 0.94)0.61 (0.45; 0.83)0.62 (0.48; 0.80)0.62 (0.36; 1.05)0.67 (0.49; 0.91)0.66 (0.48; 0.92)0.71 (0.49; 1.03)0.72 (0.43; 1.20)0.75 (0.38; 1.49)0.78 (0.53; 1.13)0.79 (0.51; 1.22)0.81 (0.58; 1.12)0.85 (0.38; 1.91)0.91 (0.69; 1.19)0.96 (0.73; 1.26)WLCN/A
0.32 (0.13; 0.80)0.34 (0.13; 0.90)0.40 (0.19; 0.86)0.44 (0.20; 0.96)0.47 (0.23; 0.96)0.50 (0.26; 0.95)0.51 (0.28; 0.93)0.50 (0.23; 1.12)0.54 (0.28; 1.04)0.54 (0.28; 1.03)0.58 (0.29; 1.13)0.58 (0.28; 1.23)0.61 (0.26; 1.44)0.63 (0.32; 1.24)0.64 (0.31; 1.34)0.66 (0.40; 1.09)0.70 (0.25; 1.90)0.74 (0.39; 1.39)0.78 (0.43; 1.40)0.81 (0.45; 1.49)D/L
  • Relative risk with 95% CIs in parentheses. Comparisons, column versus row, should be read from left to right, and are ordered relative to their overall efficacy. The treatment in the top left position is ranked as best after the network meta-analysis of direct and indirect effects. Direct comparisons are provided above the strategy labels, and indirect comparisons are below.

  • ACT, acceptance and commitment therapy; CBT, cognitive–behavioural therapy; CM, contingency management; D/L, dietary and/or lifestyle advice; DPT, dynamic psychotherapy; E/S, education and/or support; F-t-F, face-to-face; HT, hypnotherapy; IBS, irritable bowel syndrome; MM, mindfulness meditation; MPT, multicomponent psychological therapy; N/A, not applicable; RC, routine care; RT, relaxation therapy; S-A/MC, self-administered/minimal contact; SM, stress management; WLC, waiting list control.